Boulegeris Investments’s Novartis NVS Stock Holding History

Boulegeris Investments’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-3,444	Closed	-$225K	–	54
2016 Q4	$225K	Sell	3,444 -13,954	-80%	-$905K	0.14%	48
2016 Q3	$1.23M	Sell	17,398 -12,947	-43%	-$943K	0.78%	28
2016 Q2	$2.24M	Sell	30,345 -29,663	-49%	-$2.05M	1.53%	16
2016 Q1	$3.9M	Sell	60,008 -7,204	-11%	-$490K	2.74%	11
2015 Q4	$5.18M	Sell	67,212 -1,223	-2%	-$97.2K	3.76%	10
2015 Q3	$5.64M	Sell	68,435 -3,583	-5%	-$319K	4.31%	10
2015 Q2	$6.35M	Buy	72,018 +1,411	+2%	+$129K	4.55%	8
2015 Q1	$6.24M	Buy	70,607 +4,670	+7%	+$414K	4.6%	9
2014 Q4	$5.47M	Buy	65,937 +6,172	+10%	+$512K	4.36%	9
2014 Q3	$5.04M	Buy	+59,765	New	+$4.84M	4.11%	11

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Boulegeris Investments's NVS Position: Q1 2017 in Review

Boulegeris Investments sold out of Novartis (NVS) in Q1 2017, closing a stake of 3,444 shares — an estimated $225K sold.

Boulegeris Investments first reported a position in NVS in Q3 2014 and held it in 10 quarters. The position peaked at $6.35M in Q2 2015. 909 funds tracked by Wall St. Rank hold NVS as of Q1 2017.

Boulegeris Investments reported no remaining Novartis position as of Q1 2017 after selling out during the quarter.
Boulegeris Investments sold 3,444 Novartis shares in Q1 2017, an estimated $225K.
Boulegeris Investments first reported a position in Novartis in Q3 2014 and held it in 10 quarters.
Boulegeris Investments's Novartis position peaked at $6.35M in Q2 2015.
909 funds tracked by Wall St. Rank held Novartis as of Q1 2017.

Based on Boulegeris Investments's 13F filing for Q1 2017, filed 4 May 2017.